Thyroid Storm with Diarrhea, Nausea, Vomiting, Jaundice, or Elevated Bilirubin — When Initial GI and Hepatic Therapy Has Not Achieved Its Targets

This protocol addresses thyroid storm in patients who develop gastrointestinal or hepatic manifestations, and in whom the initial management directed at those manifestations has not reached its clinical goals.

Clinical scenario

Thyroid storm presenting with nausea, vomiting, diarrhea, jaundice, or a total bilirubin level ≥ 3.0 mg/dL — gastrointestinal and hepatic findings that indicate a more severe and complex presentation.

When prior therapy did not achieve its targets

The initial line addresses these GI and hepatic findings using acid-suppressive drugs (proton pump inhibitors or histamine-2 receptor antagonists) for prevention of gastrointestinal hemorrhage, alongside ursodeoxycholic acid and Stronger Neo-Minophagen C for hepatic damage.

When that approach fails to achieve resolution of gastrointestinal symptoms and reduction in total bilirubin level, this next-line protocol is indicated.

Next-line approach (partial overview)

When adequate reduction in thyroid hormone levels cannot be achieved, an extracorporeal intervention targeting acute hepatic failure — aimed at removing excess thyroid hormone, autoantibodies, and pro-inflammatory cytokines — is considered; the complete protocol specifies the modalities and decision criteria.

Treatment targets

The clinical goals at this stage are reduction in serum thyroid hormone levels and reduction in total bilirubin.

Instant Access to Structured Evidence-Based Regimens

References

Gastrointestinal (GI)/hepatic manifestations : nausea , vomiting, diarrhea, or a total bilirubin level ≥ 3.0 mg/dL

When an ade-quate reduction in thyroid hormone levels cannot be achieved, TPE and/or CHDF should be considered to remove excess thyroid hormone, autoantibodies, mol-ecules that cause coma, and pro-inflammatory cyto-kines.

Differential diagnosis for the origin of hepatic dysfunction and appropriate treatment based on its origin should be per-formed, including TPE for acute hepatic failure.

View source ↗